Royalty Pharma plc Class A Ordinary Shares
RPRXRoyalty Pharma plc (RPRX) is a pharmaceutical royalty financial company that acquires royalties from commercialized medicines, biotechnological innovations, and research and development programs. Established as a leading player in the royalty monetization sector, it provides capital to biopharmaceutical companies and researchers while generating revenue from the royalties it holds on successful drug sales.
Dividend History
Investors can expect a dividend payout of $0.23 per share, scheduled to be distributed in 46 days on March 10, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 10, 2026 | $0.23 | 2026-02-20 | 2026-02-20 |
| December 10, 2025 | $0.22 | 2025-11-14 | 2025-11-14 |
| September 10, 2025 | $0.22 | 2025-08-15 | 2025-08-15 |
| June 10, 2025 | $0.22 | 2025-05-16 | 2025-05-16 |
| March 10, 2025 | $0.22 | 2025-02-21 | 2025-02-21 |
Dividends Summary
- Consistent Payer: Royalty Pharma plc Class A Ordinary Shares has rewarded shareholders with 23 dividend payments over the past 6 years.
- Total Returned Value: Investors who held RPRX shares during this period received a total of $4.50 per share in dividend income.
- Latest Payout: The most recent dividend of $0.23/share was paid 44 days ago, on December 10, 2025.
- Yield & Schedule: RPRX currently pays dividends quarterly with an annual yield of 2.23%.
- Dividend Growth: Since 2020, the dividend payout has grown by 56.7%, from $0.15 to $0.23.
- Dividend Reliability: RPRX has maintained or increased its dividend for 23 consecutive payments.
Company News
Teva Pharmaceutical Industries will present its transformation strategy and growth outlook through 2030 at the J.P. Morgan Healthcare Conference. The company expects 2025 revenues of $16.8-$17.0 billion with operating margins of 26.2-27.1%, driven by innovative brands like AUSTEDO, AJOVY, and UZEDY. Teva targets investment-grade credit rating and...
Royalty Pharma and Teva announced a funding agreement of up to $500 million to accelerate clinical development of TEV-'408, an anti-IL-15 antibody candidate for vitiligo and celiac disease. The deal includes $75 million for Phase 2b funding with an option for an additional $425 million for Phase 3 development, contingent on Phase 2b results.
Teva Pharmaceuticals and Royalty Pharma announced a funding agreement worth up to $500 million to accelerate clinical development of TEV-'408, an anti-IL-15 antibody candidate for vitiligo treatment. The deal includes $75 million for Phase 2b funding with an option for an additional $425 million for Phase 3 development. TEV-'408 is currently in P...
Royalty Pharma (NASDAQ: RPRX) announced a 6.8% increase in its quarterly dividend to $0.235 per Class A ordinary share for Q1 2026. The dividend will be paid on March 10, 2026 to shareholders of record as of February 20, 2026.
Merck & Co. is in advanced talks to acquire cancer drug-maker Revolution Medicines for $28-32 billion, marking potentially the largest biotech M&A deal since Pfizer's $43 billion Seagen acquisition in 2023. Revolution Medicines' stock surged 15.14% overnight on the news. The deal reflects Merck's acquisition strategy amid an industry patent cliff...
